DBV TECHNOLOGIES SA-SPON ADR (DBVT)

US23306J2006 - ADR

3.19  +0.14 (+4.59%)

Premarket: 3.21 +0.02 (+0.63%)

Fundamental Rating

2

Overall DBVT gets a fundamental rating of 2 out of 10. We evaluated DBVT against 565 industry peers in the Biotechnology industry. DBVT may be in some trouble as it scores bad on both profitability and health. DBVT is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DBVT has reported negative net income.
In the past year DBVT has reported a negative cash flow from operations.
In the past 5 years DBVT always reported negative net income.
In the past 5 years DBVT always reported negative operating cash flow.

1.2 Ratios

DBVT has a Return On Assets of -63.70%. This is in the lower half of the industry: DBVT underperforms 61.92% of its industry peers.
DBVT has a Return On Equity of -91.83%. This is comparable to the rest of the industry: DBVT outperforms 48.22% of its industry peers.
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROIC N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

DBVT has a Gross Margin of 95.70%. This is amongst the best in the industry. DBVT outperforms 96.09% of its industry peers.
DBVT's Gross Margin has been stable in the last couple of years.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%

More info and screens

3

2. Health

2.1 Basic Checks

DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DBVT has been increased compared to 1 year ago.
Compared to 5 years ago, DBVT has more shares outstanding
DBVT has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.03, we must say that DBVT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.03, DBVT perfoms like the industry average, outperforming 58.54% of the companies in the same industry.
DBVT has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
DBVT has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: DBVT underperforms 64.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.03
ROIC/WACCN/A
WACC7.38%

2.3 Liquidity

A Current Ratio of 3.29 indicates that DBVT has no problem at all paying its short term obligations.
DBVT has a Current ratio of 3.29. This is in the lower half of the industry: DBVT underperforms 60.32% of its industry peers.
A Quick Ratio of 3.29 indicates that DBVT has no problem at all paying its short term obligations.
The Quick ratio of DBVT (3.29) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29

More info and screens

5

3. Growth

3.1 Past

The earnings per share for DBVT have decreased strongly by -277.22% in the last year.
The Revenue has grown by 224.69% in the past year. This is a very strong growth!
DBVT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.50% yearly.
EPS 1Y (TTM)-277.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-512.9%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%

3.2 Future

Based on estimates for the next years, DBVT will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.03% on average per year.
Based on estimates for the next years, DBVT will show a very strong growth in Revenue. The Revenue will grow by 88.16% on average per year.
EPS Next Y-542.15%
EPS Next 2Y-111.87%
EPS Next 3Y127.19%
EPS Next 5Y17.03%
Revenue Next Year13.08%
Revenue Next 2Y478.54%
Revenue Next 3Y481.18%
Revenue Next 5Y88.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBVT. In the last year negative earnings were reported.
Also next year DBVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

DBVT's earnings are expected to grow with 127.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-111.87%
EPS Next 3Y127.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DBVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (12/20/2024, 8:04:52 PM)

Premarket: 3.21 +0.02 (+0.63%)

3.19

+0.14 (+4.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2024-07-30/amc
Earnings (Next)N/A N/A
Inst Owners41.39%
Inst Owner Change-5.51%
Ins Owners0.15%
Ins Owner Change16.51%
Market Cap65.45M
Analysts82.86
Price Target8.52 (167.08%)
Short Float %N/A
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.87%
Min EPS beat(2)-68.32%
Max EPS beat(2)10.57%
EPS beat(4)2
Avg EPS beat(4)-38.33%
Min EPS beat(4)-162.56%
Max EPS beat(4)67%
EPS beat(8)5
Avg EPS beat(8)-27.78%
EPS beat(12)7
Avg EPS beat(12)-15.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-20.42%
Min Revenue beat(2)-29.38%
Max Revenue beat(2)-11.45%
Revenue beat(4)2
Avg Revenue beat(4)690.02%
Min Revenue beat(4)-29.38%
Max Revenue beat(4)2602.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)152.42%
PT rev (3m)121.81%
EPS NQ rev (1m)-368.96%
EPS NQ rev (3m)-368.96%
EPS NY rev (1m)-368.96%
EPS NY rev (3m)-422.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.16
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-5.04
FCFYN/A
OCF(TTM)-4.92
OCFYN/A
SpS0.77
BVpS3.86
TBVpS3.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.7%
FCFM N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 15.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -1.03
F-Score3
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)11.98%
Cap/Sales(5y)19.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-277.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-512.9%
EPS Next Y-542.15%
EPS Next 2Y-111.87%
EPS Next 3Y127.19%
EPS Next 5Y17.03%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%
Revenue Next Year13.08%
Revenue Next 2Y478.54%
Revenue Next 3Y481.18%
Revenue Next 5Y88.16%
EBIT growth 1Y20.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y56.49%
EBIT Next 5YN/A
FCF growth 1Y-50.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.06%
OCF growth 3YN/A
OCF growth 5YN/A